Executive Summary: The Dual Challenge of Compliance and Strategy

The global pharmaceutical landscape of 2025 is defined by a paradoxical dynamic: regulatory harmonization on one hand, and increasing market complexity on the other. For pharmaceutical professionals operating at the intersection of the United States and Germany—Europe’s largest pharmaceutical market—the environment has never been more intricate. The convergence of manufacturing standards through the FDA-EU Mutual Recognition Agreement (MRA) offers unprecedented efficiency in logistics and quality assurance. Yet, simultaneously, the commercial environment within Germany has been fundamentally reshaped by the Medical Research Act (Medizinforschungsgesetz – MFG) and the Act to Combat Supply Shortages (ALBVVG), introducing new layers of strategic calculation regarding pricing, transparency, and supply chain resilience.

This report serves as a definitive guide for regulatory affairs directors, market access managers, and commercial strategists who must navigate this terrain. It explores the operational realities of the “ABDA Germany” ecosystem—the digital and political backbone of the German pharmacy market—and dissects the “FDA Germany” collaboration that dictates the flow of goods across the Atlantic. Furthermore, it posits that in this era of high-velocity regulatory change, static data is a liability. The key to commercial survival lies in dynamic, integrated intelligence—a capability epitomized by tools like pharmazie.com’s Iceberg Search, which aggregates the fragmented data of the Lauer-Taxe, BfArM, and G-BA into a coherent strategic picture.

We will traverse the entire value chain: from the granular coding of a PZN (Pharmazentralnummer) to the high-stakes poker game of confidential AMNOG price negotiations. This analysis is designed not merely to inform, but to empower you to make data-driven decisions that secure market access and optimize revenue in the Federal Republic.

Part I: The ABDA Ecosystem – The Institutional and Digital Nervous System of German Pharmacy

To operate successfully in Germany, one must first internalize the centrality of the ABDA – Bundesvereinigung Deutscher Apothekerverbände (Federal Union of German Associations of Pharmacists). While international observers often mistake it for a mere trade association, the ABDA is, in functional terms, the operating system of the German pharmaceutical distribution network. It represents the unified political voice of the profession while simultaneously managing the data standards that make the dispensing of medication possible.

1.1 The Institutional Architecture: Representation and Mandate

The ABDA acts as the umbrella organization for 34 member organizations, comprising 17 State Chambers of Pharmacists (Landesapothekerkammern) and 17 State Associations of Pharmacists (Landesapothekerverbände). This dual structure is unique and critical for understanding how policy translates into practice. The Chambers, where membership is mandatory for every licensed pharmacist, are responsible for professional ethics, continuing education, and quality assurance. The Associations, where membership is voluntary but widespread among pharmacy owners, handle the commercial negotiations with statutory health insurers (GKV).

The Mandate of Universal Supply

Germany’s pharmacy network is governed by a strict legislative mandate: to ensure the proper supply of medicinal products to the entire population, at all times. As of 2025, the network consists of approximately 17,500 community pharmacies. While this represents a consolidation from the peak of nearly 21,500 in 2008, the network remains robust, providing a density of roughly 22 pharmacies per 100,000 inhabitants. This figure places Germany in the mid-range of European density—below the highly fragmented markets of Spain (47 per 100,000) and France (30 per 100,000), but significantly above the consolidated chains of the UK or the Netherlands.

For a US-based manufacturer, this density has immediate logistical implications. Unlike the US market, where distribution can be centralized through massive pharmacy benefit managers (PBMs) and chain warehouses, the German market relies on a finely tuned system of full-line wholesalers delivering to thousands of independent “Apotheken” multiple times a day. The ABDA monitors this network relentlessly to argue against deregulation, using data to demonstrate that purely mail-order models cannot sustain the acute care infrastructure required for night and emergency services.

The Human Element: Pharmacists as Gatekeepers

The role of the pharmacist in Germany is expanding. With the introduction of “Pharmaceutical Care Services” (Pharmazeutische Dienstleistungen), pharmacists are now reimbursed for medication reviews, inhalation training, and blood pressure monitoring. This shift elevates the pharmacist from a dispenser to a clinical stakeholder. Consequently, the data they access at the Point of Sale (POS) regarding a drug—its interactions, its application advice, its “Priscus List” status for elderly patients—becomes a decisive factor in therapy adherence and brand perception. This data is fed exclusively through the ABDA Database.

1.2 The ABDA Database (ABDATA): The Gold Standard of Pharmaceutical Data

When industry insiders discuss “ABDA Germany,” they are frequently referring to ABDATA Pharma-Daten-Service, the subsidiary responsible for the ABDA Database. This is not simply a reference catalog; it is the digital infrastructure that underpins every transaction in the German healthcare market.

The database contains comprehensive information on over 50,000 German finished medicinal products and more than 120,000 internationally marketed products.6 It is the source of truth for:

• Wholesalers: To manage logistics and stock.
• Pharmacies: To process prescriptions, check interactions, and bill insurers.
• Insurers: To validate claims and calculate rebates.
• Software Vendors: To power the ERP systems used across the sector.

The Article Master (Artikelstamm) 

At the heart of the ABDA Database lies the Article Master. For a Market Access Manager, mastering the ABDA Artikelstamm is non-negotiable. It dictates the economic parameters of every product.

1. The PZN (Pharmazentralnummer): The Key to the Kingdom

The PZN is the 8-digit unique identifier for medicinal products in Germany. Unlike the US National Drug Code (NDC), which segments by labeler and product, the PZN is a sequential identifier issued by the IFA (Informationsstelle für Arzneispezialitäten) but managed within the ABDA architecture.

• Requirement: A product without a PZN effectively does not exist in the German statutory system. It cannot be billed, it cannot be ordered via standard wholesale interfaces (MSV3), and it cannot be scanned at the counter.
• Structure: The PZN is integrated into the Data Matrix Code required for serialization under the EU Falsified Medicines Directive (FMD), linking the physical pack to its digital twin in the ABDA database.

2. The Pricing Hierarchy

The ABDA Article Master maintains the legally binding price points for every drug:

• ApU (Abgabepreis des pharmazeutischen Unternehmers): The ex-factory price.
• AEK (Apothekeneinkaufspreis): The purchase price for the pharmacy, regulated by the Pharmaceutical Price Ordinance (Arzneimittelpreisverordnung).
• AVP (Apothekenverkaufspreis): The retail price, which serves as the basis for reimbursement.

Crucially, the database is updated bi-weekly (on the 1st and 15th of every month). In a volatile regulatory environment where reference prices or rebate contracts can change overnight, relying on a monthly or quarterly data dump is a recipe for compliance failure. This is where the integrated, real-time nature of platforms like pharmazie.com becomes a strategic asset, ensuring that your pricing strategy is always synchronized with the official Lauer-Taxe updates.

Clinical Decision Support: CAVE and Interactions

Beyond economics, the ABDA Database is a clinical safety tool. The CAVE module (Chemical and Veterinary Safety) provides automated checks for contraindications, allergies, and age-appropriateness.

• Interaction Checking: When a pharmacist scans a drug, the system cross-references the patient’s medication history against the ABDA Interaction Module. If a severe interaction is flagged, the dispensing may be halted.
• Strategic Implication: Manufacturers must ensure their interaction data is accurately reflected in the ABDA dossiers. A “false positive” interaction flag in the system can lead to widespread substitution of a product at the counter, purely due to data inaccuracy.

1.3 The “Iceberg” Challenge: Resolving Data Fragmentation

While the ABDA Database is comprehensive, it is not all-encompassing. The German market suffers from severe data fragmentation. Pricing data sits in the Lauer-Taxe; benefit assessment resolutions sit with the G-BA; supply shortage reports sit with the BfArM; and rebate contracts sit with individual insurance funds.

This creates the “Iceberg” phenomenon: The visible PZN and price are just the tip. The massive bulk of regulatory constraints—AMNOG ratings, supply status, international reference prices, interaction profiles—lies beneath the surface, scattered across disparate sources.

The Solution: Aggregated Intelligence

This is the core value proposition of pharmazie.com’s Iceberg Search. By aggregating these siloed datasets into a single, multidimensional search engine, it allows users to see the entire iceberg.

• Semantic Interoperability: A US Regulatory Director can search for “Acetaminophen” and the system will intelligently map it to “Paracetamol,” identifying all German trade names, their prices, their reimbursement status, and their current supply availability.
• Global Context: The tool links the German data to international databases (e.g., Austria Codex, Swiss Drug Dictionary), allowing for immediate cross-border price comparisons—a critical capability for managing the risk of parallel trade.

Part II: Transatlantic Regulatory Convergence – The FDA and Germany in the Era of Mutual Recognition

While the ABDA governs the internal market, the flow of pharmaceutical products between Germany and the United States is governed by the relationship between the US Food and Drug Administration (FDA) and Germany’s competent authorities: the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institut (PEI).

For decades, this relationship was characterized by redundancy. A manufacturing plant in Bavaria producing tablets for the US market would be inspected by the local German state authority (Regierungspräsidium) for EU compliance, and then separately by FDA investigators for US compliance. This duplication wasted millions in resources and delayed market entry. Today, thanks to the Mutual Recognition Agreement (MRA), we have entered a new era of efficiency.

2.1 The Mutual Recognition Agreement (MRA): A Historical Achievement

The path to mutual recognition was long and arduous. The initial 1998 agreement stalled due to differences in inspection rigor and confidence. However, the initiative was revived under the FDA Safety and Innovation Act of 2012, leading to the full implementation of the Sectoral Annex for Pharmaceutical Good Manufacturing Practices (GMP) starting in 2017.

The Assessment Process

The FDA did not issue a blanket recognition of “Europe.” Instead, it conducted a granular capability assessment of every single EU Member State’s inspectorate. For Germany, this was particularly complex due to its federal structure, where 16 different state authorities are responsible for GMP oversight, coordinated by the ZLG (Zentralstelle der Länder für Gesundheitsschutz).

• Milestone: On June 26, 2019, the FDA officially confirmed the capability of Germany’s inspectorates. This marked the turning point where FDA investigators could officially rely on German inspection reports in lieu of conducting their own foreign inspections.

Scope and Expansion (2025 Status)

As of 2025, the MRA covers a broad spectrum of products, and its scope has recently expanded:

• Human Medicines: Fully operational since July 2019. This includes chemical pharmaceuticals and certain biological products.
• Veterinary Medicines: In a major development, the FDA and EU expanded the MRA to include veterinary pharmaceuticals in May 2023. Germany was among the first wave of countries recognized for veterinary GMP capability, meaning that animal health companies now benefit from the same streamlined oversight.
• Vaccines and Plasma: Work continues on expanding the scope to include vaccines and plasma-derived products, areas previously excluded due to their high-risk nature.

2.2 The Batch Testing Waiver: Unlocking Supply Chain Velocity

For logistics managers and Quality Ps (Qualified Persons), the most tangible benefit of the MRA is the Batch Testing Waiver.

• The Old Way: Under EU Directive 2001/83/EC, every batch of medicinal product imported from outside the EU (a “third country”) had to undergo full qualitative and quantitative re-testing upon arrival in the EU, regardless of the testing already performed by the manufacturer.
• The MRA Way: Article 9 of the Sectoral Annex allows this requirement to be waived. A Qualified Person in Germany can now certify a batch for release based solely on the Certificate of Analysis (CoA) from the US manufacturer, provided they have verified that the US site is compliant and inspections are mutually recognized.

Economic Impact: This waiver eliminates days, sometimes weeks, from the supply chain and saves thousands of Euros per batch in laboratory fees. However, implementation requires rigorous documentation. The QP must have access to the inspection history of the US site—data that can be verified through the FDA’s databases and cross-referenced with German import permits.

2.3 The FDA Europe Office and BfArM Collaboration

The “FDA Germany” search intent often stems from a need to contact the FDA locally. It is important to clarify that there is no standalone “FDA Germany” office. Instead, the FDA Europe Office manages relations with Germany from its hubs in Brussels (US Mission to the EU) and Amsterdam (at the EMA).

Deepening Collaboration: Beyond GMP

The relationship extends far beyond manufacturing inspections. The FDA and BfArM have signed robust Confidentiality Commitments that allow for the exchange of unredacted reports and trade secrets.

• Clinical Trial Oversight (GCP): The agencies collaborate on Good Clinical Practice (GCP) inspections. If a pivotal trial for a US submission is conducted in German hospitals, the FDA may rely on BfArM’s GCP inspection results. This is critical for the “Medical Research Act” strategy (discussed in Part IV), which incentivizes conducting trials in Germany.
• Bioequivalence Inspections: A specific initiative targets the inspection of facilities conducting bioequivalence studies for generic applications, ensuring that the data supporting generic approvals in both markets is robust.

2.4 Case Study: The “Milk Thistle” Paradox

To illustrate the nuances of the FDA-Germany relationship, consider the market for Milk Thistle (Silybum marianum).

• In Germany: Milk Thistle extracts are frequently regulated as fully licensed herbal medicines (Phytopharmaka) with a specific PZN, approved indications for liver support, and strictly controlled quality standards documented in the ABDA Database.
• In the US: The FDA often regulates these same products as “Dietary Supplements” under DSHEA, a category with different GMP requirements (21 CFR 111 vs. 21 CFR 210/211) and no pre-market approval for efficacy.
• The Conflict: A German manufacturer exporting a licensed Milk Thistle medicine to the US cannot simply sell it as a drug without an NDA, nor can they automatically sell it as a supplement without ensuring the labeling meets FDA supplement regulations. Conversely, a US supplement manufacturer cannot sell their product in German pharmacies as a “medicine” without a full marketing authorization.
• The Data Solution: Using pharmazie.com’s Iceberg Search, a regulatory specialist can instantly identify the legal status of Milk Thistle products in Germany, view their specific “Apothekenpflicht” (pharmacy-only) status, and access the German SmPC to understand the claims allowed by BfArM—vital intelligence for bridging the regulatory gap.

Part III: Market Access Germany 2025 – The Revolution of the Medical Research Act (MFG)

While the ABDA ensures products can be distributed, and the FDA ensures they can be manufactured, the AMNOG process determines whether they can be sold profitably. Germany is unique among major markets: it allows immediate market launch and reimbursement upon approval, but the price is set retrospectively through a rigorous benefit assessment.

In 2025, this system underwent its most radical transformation since its inception in 2011. The Medical Research Act (Medizinforschungsgesetz – MFG) has rewritten the rules of the game.

3.1 The AMNOG Process (2011–2024): The Context of Reform

To understand the 2025 changes, one must understand the pressure cooker that preceded them. The AMNOG process involves three stages:

1. Benefit Assessment: The Federal Joint Committee (G-BA) assesses the “Added Benefit” against a comparator.
2. Negotiation: The GKV-Spitzenverband (funds) negotiates a discount based on that benefit.
3. Arbitration: If negotiations fail, a board sets the price.

In 2022, the GKV-Financial Stabilization Act (GKV-FinStG) introduced strict “guardrails.” If a drug was found to have “No Added Benefit,” its price was capped below the generic comparator. Even innovative drugs faced mandatory rebates and inflation freezes. This led to an exodus of innovation; several major companies withdrew products from the German market rather than accept a price that would destroy their global reference pricing floor.

3.2 The Medical Research Act (MFG) 2025: Strategic Decoupling

The MFG was the government’s answer to this crisis. It introduces two mechanisms designed to keep innovation in Germany while protecting the payer system: Confidential Reimbursement Prices and the Removal of International Reference Pricing.

The Confidentiality Option (Vertraulicher Erstattungsbetrag)

For the first time, companies can choose to keep their negotiated reimbursement price secret.

• The Mechanism: Within five days of concluding the price negotiation, the pharmaceutical company can request confidentiality. The “official” price in the Lauer-Taxe remains the higher list price. The “real” price paid by insurers is the confidential discounted price.
• The Cost: This secrecy is not free. Companies opting for confidentiality must pay a 9% penalty discount on top of their negotiated rebate.
• The Logic: Why pay 9% to hide a price? Because of International Reference Pricing (IRP). If the German price is public and low, countries like Japan, France, and Canada reference it to lower their own prices. A 9% loss in Germany might save 20% of revenue in the rest of the world.

The End of the “European Basket”

To make confidentiality effective, the MFG legally removed the requirement for German negotiators to consider prices in other European countries.

• Before 2025: The GKV-Spitzenverband would argue: “You sell this for €50 in Greece, so we won’t pay €100.”
• After 2025: The German price is determined solely by the value demonstrated in the German system (AMNOG rating). This decoupling breaks the “downward spiral” of European pricing.

3.3 Incentivizing Clinical Research: The 5% Rule

The MFG also links pricing directly to research investment. It introduces a rule stating that if a pharmaceutical company conducts a “relevant part” of its clinical trials in Germany, it gains flexibility in the pricing guardrails.

• The Threshold: “Relevant part” is defined as enrolling at least 5% of the global trial population in German study centers.
• The Benefit: Achieving this threshold can exempt a drug from some of the harshest GKV-FinStG caps, potentially allowing a negotiated price even when the added benefit is “non-quantifiable” or “minor.”
• Strategic Imperative: For Clinical Operations Directors, Germany is no longer just a recruitment ground; it is a pricing lever. Excluding Germany from a Phase III trial to save on costs could now cost millions in lost reimbursement potential.

3.4 Simulation: To Hide or Not to Hide?

Imagine a new oncology drug launch.

• List Price: €10,000.
• Negotiated Discount: 20% (Net Price €8,000).
• Scenario A (Public): The €8,000 price becomes public in the Lauer-Taxe. France references it and demands €7,800. Japan demands €7,500.
• Scenario B (Confidential): The company invokes the MFG option.

• They pay an extra 9% on the €8,000, reducing the German net to €7,280.
• However, the public price remains €10,000 (or close to it).
• France and Japan reference the €10,000 list price (or the company negotiates from a higher baseline), potentially securing €9,000 in those markets.

• The Verdict: The company loses €720 per unit in Germany but gains €1,200+ per unit in every other market. The confidential option is a clear winner for global blockbusters.

Making this calculation requires precise data on international prices and reference rules. pharmazie.com’s Pricing Tools allow users to simulate these scenarios, viewing the current reference baskets and price corridors across Europe to make the optimal decision within the 5-day window.

Part IV: Supply Chain Resilience – The ALBVVG and the Fight Against Shortages

In recent years, the reputation of Germany as the “Pharmacy of the World” has been tarnished by severe supply shortages (Lieferengpässe). The reliance on Asian API manufacturers combined with aggressive cost-containment (rebate contracts) created a fragile system where a single factory outage could leave German children without fever syrup or cancer patients without tamoxifen.38

4.1 The ALBVVG: Legislative Response

The Act to Combat Supply Shortages (ALBVVG) was passed to address this. It mandates:

• Stockpiling: Manufacturers must maintain several months of safety stock for critical medicines.
• Diversification: For certain tenders (e.g., antibiotics), insurers must consider “European production” as a quality criterion, not just the lowest price.

4.2 The Role of Data in Managing Shortages

The ABDA has been instrumental in managing the crisis on the ground. Pharmacies spend an average of 10 hours per week managing shortages—calling wholesalers, checking alternatives, and documenting unavailability.

The BfArM Shortage Database:

The BfArM maintains a database of reported supply shortages.39 However, this data is often based on manufacturer self-reporting and can lag behind reality.

The Aggregator Advantage:

This is where pharmazie.com provides critical value. By integrating:

1. Official BfArM Reports: The legal status of the shortage.
2. Wholesale Availability (MSV3): The real-time stock status at the logistics center.
3. Therapeutic Equivalents: The clinical alternatives identified in the ABDA database.

The system allows a wholesaler or hospital pharmacist to instantly answer the question: “Product A is missing. What is the exact equivalent, is it in stock, and what is its price?”. For a generic manufacturer, this is a sales opportunity: monitoring competitor shortages in the system allows for the strategic positioning of one’s own inventory to fill the gap.

Part V: Strategic Synthesis and Actionable Roadmap

The convergence of these themes—ABDA data standards, FDA mutual recognition, and MFG pricing reforms—creates a high-stakes environment where intuition is insufficient. Success requires a strategy built on high-fidelity data.

5.1 The Value of “Iceberg Search” for the Modern Pharma Professional

In a fragmented market, the ability to see the whole picture is the ultimate competitive advantage. pharmazie.com’s Iceberg Search is not just a search bar; it is a strategic lens.

• For Regulatory Affairs: It validates PZN status, checks interactions in the CAVE module, and confirms FDA-relevant German approval data.
• For Market Access: It simulates the financial impact of confidential pricing and tracks the bi-weekly Lauer-Taxe updates that determine reimbursement.
• For Commercial Teams: It identifies supply gaps and competitor vulnerabilities in real-time.

5.2 The 2025 Market Entry Checklist

For US companies entering Germany, the following roadmap ensures compliance and maximizes value:

5.3 Conclusion

The German pharmaceutical market of 2025 is a fortress of regulation, but it is a fortress with keys. The ABDA Database is the map; the FDA MRA is the bridge; and the Medical Research Act is the new rulebook for the toll.

Navigating this landscape requires more than just a product; it requires intelligence. It requires the ability to connect the dots between a manufacturing inspection in New Jersey, a PZN code in Frankfurt, and a pricing negotiation in Berlin.

Don’t let data fragmentation sink your strategy. The Iceberg Search allows you to see what lies beneath the surface. To experience how integrated pharmaceutical intelligence can transform your market access and compliance operations, book a demo with pharmazie.com today.

References

1. NEW TECHNOLOGIES FOR THE MARKETING AND SALE OF MEDICINES ON THE INTERNET AND TELEVISION NETWORKS – European Parliament, Zugriff am November 26, 2025, https://www.europarl.europa.eu/RegData/etudes/etudes/join/2000/168393/DG-4-JOIN_ET(2000)168393_EN.pdf
2. Smart-Pharma-2016-2024-Complete-collection.pdf, Zugriff am November 26, 2025, https://smart-pharma.com/wp-content/uploads/2025/05/Smart-Pharma-2016-2024-Complete-collection.pdf
3. German Pharmacies: Figures Data Facts 2025 – ABDA, Zugriff am November 26, 2025, https://www.abda.de/fileadmin/user_upload/assets/ZDF/Jahrbuch-ZDF-2025/ABDA_ZDF_2025_Brosch_english.pdf?utm_source=euractiv&utm_medium=newsletter&utm_content=the_capitals&utm_term=0-1&utm_campaign=PRO_Health
4. Milk Thistle Market Size, Share, Industry, Forecast and outlook (2024-2031), Zugriff am November 26, 2025, https://www.datamintelligence.com/research-report/milk-thistle-market
5. Milk Thistle Market Anticipates Substantial Growth with a – GlobeNewswire, Zugriff am November 26, 2025, https://www.globenewswire.com/news-release/2023/10/16/2760847/0/en/Milk-Thistle-Market-Anticipates-Substantial-Growth-with-a-Projected-Value-of-US-316-35-Million-by-2033-Showing-an-Impressive-8-3-CAGR-From-2023-to-2033-Future-Market-Insights-Inc.html
6. ABDA Database – Pharmazie.com, Zugriff am November 26, 2025, https://go.pharmazie.com/en/abda-database/
7. The univocal identification and safe dispensation of medicinal products across Europe – challenges and solution proposal | Publisso, Zugriff am November 26, 2025, https://series.publisso.de/en/journals/mibe/volume13/mibe000176
8. AMNOG Reimbursement Database Europe – Unlocking Pricing & Access Data for DACH Markets – Pharmazie.com, Zugriff am November 26, 2025, https://go.pharmazie.com/en/amnog-reimbursement-database-europe/
9. Carbon footprint of package leaflets – IGES Institut, Zugriff am November 26, 2025, https://www.iges.com/sites/igesgroup/iges.de/myzms/content/e6/e1621/e10211/e29580/e57380/e57381/e57383/attr_objs57385/PI11_23_SD-PDF_Dobersetal_29Nov23_ger.pdf
10. A Comprehensive Guide to Pharmazentralnummer (PZN) – Online Tool Center, Zugriff am November 26, 2025, https://www.onlinetoolcenter.com/blog/A-Comprehensive-Guide-to-Pharmazentralnummer-PZN.html
11. Guidelines for Notifying Product and Address Data – Informationsstelle für Arzneispezialitäten IFA GmbH, Zugriff am November 26, 2025, https://www.ifaffm.de/mandanten/1/documents/02_ifa_anbieter/richtlinien/IFA-Guidelines_Data-Notification_EN.pdf
12. Guidelines for the Serialisation of Medicinal Products – GS1 Germany, Zugriff am November 26, 2025, https://www.gs1-germany.de/fileadmin/gs1/fachpublikationen/gs1-guidelines-for-the-serialisation-of-medicinal-products.pdf
13. CODING RULES FOR MEDICINES REQUIRING VERIFICATION FOR THE GERMAN MARKET – securPharm, Zugriff am November 26, 2025, https://www.securpharm.de/wp-content/uploads/2019/01/securPharm_Codierung_Regeln_EN_V2_04a.pdf
14. Drug Pricing Database Germany – Integrated Pharmaceutical …, Zugriff am November 26, 2025, https://go.pharmazie.com/en/drug-pricing-database-germany-lt/
15. Icebergsearch – all drug information with one click in this search engine – Pharmazie.com, Zugriff am November 26, 2025, https://go.pharmazie.com/en/product/icebergsearch/
16. Most comprehensive Drug Data for Pharma | pharmaze.com – pharmazie.com, Zugriff am November 26, 2025, https://go.pharmazie.com/
17. Mutual Recognition Agreements (MRA) – FDA, Zugriff am November 26, 2025, https://www.fda.gov/international-programs/international-arrangements/mutual-recognition-agreements-mra
18. Mutual Recognition Agreement / Frequently Asked Questions and Answers January 2021 – FDA, Zugriff am November 26, 2025, https://www.fda.gov/media/103391/download
19. Questions & Answers on the impact of Mutual Recognition Agreement (MRA) between the European Union and the United States as of 1st October 2025, Zugriff am November 26, 2025, https://www.ema.europa.eu/en/documents/other/questions-answers-impact-mutual-recognition-agreement-mra-between-european-union-united-states-1st-october-2025_en.pdf
20. EU and US reach a milestone in mutual recognition of inspections of medicines manufacturers – implications for QPs – Asepharmasolutions EN, Zugriff am November 26, 2025, http://en.asepharmasolutions.com/blog/2019/08/29/eu-us-mra-inspections-of-medicines-manufacturers/
21. European Union (EU) Mutual Recognition Agreement – FDA, Zugriff am November 26, 2025, https://www.fda.gov/international-programs/international-arrangements/european-union-eu-mutual-recognition-agreement
22. Mid-year report 2025 | European Medicines Agency (EMA), Zugriff am November 26, 2025, https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2025-january-june-2025_en.pdf
23. Mutual recognition agreements (MRA) | European Medicines Agency (EMA), Zugriff am November 26, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/mutual-recognition-agreements-mra
24. Sections and Offices – U.S. Mission to the European Union, Zugriff am November 26, 2025, https://useu.usmission.gov/sections-and-offices/
25. Ritu Nalubola | FDA, Zugriff am November 26, 2025, https://www.fda.gov/about-fda/fda-organization/ritu-nalubola
26. BfArM Germany – FDA, Confidentiality Commitment, Zugriff am November 26, 2025, https://www.fda.gov/international-programs/confidentiality-commitments/bfarm-germany-fda-confidentiality-commitment
27. The Federal Institute for Drugs and Medical Devices (BfArM) – FDA, Confidentiality Commitment, Zugriff am November 26, 2025, https://www.fda.gov/international-programs/confidentiality-commitments/federal-institute-drugs-and-medical-devices-bfarm-fda-confidentiality-commitment
28. GCP Inspections Unit – BfArM, Zugriff am November 26, 2025, https://www.bfarm.de/EN/Medicinal-products/GCP-Inspections-Unit/_node.html
29. Terms of engagement EMA-EU MSs-FDA initiative on inspections for Generic Applications, Zugriff am November 26, 2025, https://www.fda.gov/media/87824/download
30. AMNOG Benefit Assessment Archive – WS Value & Dossier GmbH, Zugriff am November 26, 2025, https://value-dossier.com/en/category/amnog-benefit-assessment/
31. Germany: Pharma Policy Updates—Brand Rebates & Confidential Discounts, Zugriff am November 26, 2025, https://trinitylifesciences.com/blog/rise-with-the-waves-germany-a-tale-of-two-high-impact-policies/
32. Debunking value, access, and pricing myths: Episode 2 | Pricing in Germany is always transparent – IQVIA, Zugriff am November 26, 2025, https://www.iqvia.com/blogs/2025/08/debunking-value-access-and-pricing-myths-episode-2
33. Germany 2025: Pricing Innovation & Evidence in Pharmaceutical Access, Zugriff am November 26, 2025, https://trinitylifesciences.com/blog/germany-innovative-medicines-evidence/
34. European Reference Pricing is discontinued in Germany – WS Value Dossier GmbH, Zugriff am November 26, 2025, https://value-dossier.com/en/european-reference-pricing-is-discontinued-in-germany/
35. All change in Germany – confidential pricing in, IRP out – Pharmaceutical Technology, Zugriff am November 26, 2025, https://www.pharmaceutical-technology.com/analyst-comment/all-change-germany-confidential-pricing-irp/
36. Germany amends drug pricing and reimbursement laws with “Medical Research Act” – Drug pricing becomes intertwined with local clinical research expectations | Inside EU Life Sciences, Zugriff am November 26, 2025, https://www.insideeulifesciences.com/2024/07/12/germany-amends-drug-pricing-and-reimbursement-laws-with-medical-research-act-drug-pricing-becomes-intertwined-with-local-clinical-research-expectations/
37. Pricing & Reimbursement Laws and Regulations 2025 – Germany – Global Legal Insights, Zugriff am November 26, 2025, https://www.globallegalinsights.com/practice-areas/pricing-reimbursement-laws-and-regulations/germany/
38. Drug shortages: clinical implications and burdens – a trinational multiple-methods study including key stakeholders – PubMed Central, Zugriff am November 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12459160/
39. Supply shortages – BfArM, Zugriff am November 26, 2025, https://www.bfarm.de/EN/Medicinal-products/Information-on-medicinal-products/Supply-shortages/_node.html
40. Drug Shortage Database Germany – A Comprehensive Solution to Medicine Supply Gaps, Zugriff am November 26, 2025, https://go.pharmazie.com/en/drug-shortage-database-germany/